Clinical Features, Treatment, and Outcomes of Mucormycosis: A Retrospective Analysis of 13 Cases from a Single Center in Turkey (2015–2025) †
Esma Kepenek Kurt, Rukiyye Bulut, Bahar Kandemir, İbrahim Erayman · 2026
Read Clinical Features, Treatment, and Outcomes of Mucormycosis: A Retrospective Analysis of 13 Cases from a Single Center in Turkey (2015–2025) † by Esma Kepenek Kurt, Rukiyye Bulut, Bahar Kandemir, İbrahim Erayman (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13308116.txt.
Description
Esma Kepenek Kurt and co-authors review thirteen mucormycosis cases treated at one Turkish centre between 2015 and 2025 in a 2026 report. The invasive fungal infection struck mostly men, and every patient reported facial pain. Blood cancers were the commonest background condition, followed by diabetes and earlier COVID-19 pneumonia.
Surgery reached most patients, and all received liposomal amphotericin B, with many moving on to posaconazole. Cultures grew Rhizopus or Mucor species in a minority, while tissue examination and imaging supported the diagnosis broadly. Two patients suffered recurrence. Eight of the thirteen died, including several whose infection reached the brain. The authors stress that even early diagnosis plus combined surgery and antifungals often fails. Host immune weakness, they note, drives outcomes more than any single treatment choice.
Catalog record
| CREATOR | Esma Kepenek Kurt, Rukiyye Bulut, Bahar Kandemir, İbrahim Erayman |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 23 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |